{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:49:43Z","timestamp":1788922183684,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"am","delay-in-days":302,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DA031725"],"award-info":[{"award-number":["DA031725"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.drugalcdep.2025.112799","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T06:31:55Z","timestamp":1752906715000},"page":"112799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Mu-opioid mediated discriminative stimulus effects of fentanyl and xylazine: Dose-response and time-course studies"],"prefix":"10.1016","volume":"275","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0429-2798","authenticated-orcid":false,"given":"Mark A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony G.","family":"Spera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha L.","family":"Biancorosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah N.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2025.112799_bib1","doi-asserted-by":"crossref","first-page":"09646","DOI":"10.1016\/j.drugalcdep.2022.109646","article-title":"Effects of the cannabinoid CB1-receptor neutral antagonist AM4113 and antagonist\/inverse agonist rimonabant on fentanyl discrimination in male rats","volume":"240","author":"AlKhelb","year":"2022","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2025.112799_bib2","article-title":"Xylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to opioid antagonism","volume":"11","author":"Bedard","year":"2024","journal-title":"Addict. Neurosci."},{"key":"10.1016\/j.drugalcdep.2025.112799_bib3","unstructured":"Center for Forensic Science Research & Education., 2023. Phenylbutazone: A toxic adulterant found in illicit street drugs. \u3008https:\/\/www.cfsre.org\/images\/content\/reports\/public_alerts\/Phenylbutazone_Public_Health_Alert_031323_final.pdf\u3009"},{"key":"10.1016\/j.drugalcdep.2025.112799_bib4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11916-024-01211-z","article-title":"Xylazine: a drug adulterant of clinical concern","volume":"28","author":"Edinoff","year":"2024","journal-title":"Curr. Pain. Headache Rep."},{"key":"10.1016\/j.drugalcdep.2025.112799_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12954-024-01082-y","article-title":"Syringe services program staff and participant perspectives on changing drug consumption behaviors in response to xylazine adulteration","volume":"21","author":"Eger","year":"2024","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.drugalcdep.2025.112799_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(25)32143-9","article-title":"Narcotic discrimination in pigeons","volume":"214","author":"Herling","year":"1980","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2025.112799_bib7","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/0091-3057(95)02151-5","article-title":"Discriminative-stimulus effects of morphine in combination with alpha- and beta-noradrenergic agonists and antagonists in rats","volume":"53","author":"Hughes","year":"1996","journal-title":"Pharm. Biochem Behav."},{"key":"10.1016\/j.drugalcdep.2025.112799_bib8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0091-3057(84)90182-5","article-title":"Effects of the training dose on generalization of morphine stimulus to clonidine","volume":"20","author":"Krimmer","year":"1984","journal-title":"Pharm. Biochem Behav."},{"key":"10.1016\/j.drugalcdep.2025.112799_bib9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12954-024-01097-5","article-title":"Xylazine awareness and attitudes among people who use drugs in Ohio, 2023-2024","volume":"21","author":"Michaels","year":"2024","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.drugalcdep.2025.112799_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00429187","article-title":"Generalization study with some narcotic and nonnarcotic drugs in rats trained for morphine-saline discrimination","volume":"60","author":"Miksic","year":"1978","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2025.112799_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-3565(25)12589-5","article-title":"Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists","volume":"254","author":"Picker","year":"1990","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2025.112799_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104154","article-title":"Xylazine in the drug supply: Emerging threats and lessons learned in areas with high levels of adulteration","volume":"120","author":"Quijano","year":"2023","journal-title":"Int J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2025.112799_bib13","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1111\/1556-4029.15242","article-title":"Identification of the veterinary sedative medetomidine in combination with opioids and xylazine in Maryland","volume":"68","author":"Sisco","year":"2023","journal-title":"J. Forensic Sci."},{"key":"10.1016\/j.drugalcdep.2025.112799_bib14","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/ADM.0000000000001216","article-title":"Self-reported xylazine experiences: a mixed-methods study of reddit subscribers","volume":"17","author":"Spadaro","year":"2023","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2025.112799_bib15","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1074\/jbc.M806742200","article-title":"p38 MAPK and beta-arrestin 2 mediate functional interactions between endogenous micro-opioid and alpha2A-adrenergic receptors in neurons","volume":"284","author":"Tan","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drugalcdep.2025.112799_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/JCI183354","article-title":"Xylazine induces dopamine release and augments the effects of fentanyl","volume":"134","author":"Trinko","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.drugalcdep.2025.112799_bib17","unstructured":"U.S. Sentencing Commission, 2021. Fentanyl and fentanyl analogues federal trends and trafficking patterns. \u3008https:\/\/www.ussc.gov\/research\/research-reports\/fentanyl-and-fentanyl-analogues-federal-trends-and-trafficking-patterns\u3009"},{"key":"10.1016\/j.drugalcdep.2025.112799_bib18","unstructured":"White House, 2023. FACT SHEET: In Continued Fight Against Overdose Epidemic, the White House Releases National Response Plan to Address the Emerging Threat of Fentanyl Combined with Xylazine \u3008https:\/\/www.whitehouse.gov\/briefing-room\/statements-releases\/2023\/07\/11\/fact-sheet-in-continued-fight-against-overdose-epidemic-the-white-house-releases-national-response-plan-to-address-the-emerging-threat-of-fentanyl-combined-with-xylazine\/\u3009 (accessed 03 January 2025)."},{"key":"10.1016\/j.drugalcdep.2025.112799_bib19","first-page":"6","article-title":"Evaluation of morphine-like effects of the mixed mu\/delta agonist morphine-6-O-sulfate in rats: drug discrimination and physical dependence","author":"Yadlapalli","year":"2018","journal-title":"Pharm. Res Perspect."},{"key":"10.1016\/j.drugalcdep.2025.112799_bib20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s002130050035","article-title":"Discriminative stimulus effects of two doses of fentanyl in rats: pharmacological selectivity and effect of training dose on agonist and antagonist effects of mu opioids","volume":"148","author":"Zhang","year":"2000","journal-title":"Psychopharmacology"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625002522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625002522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:58:03Z","timestamp":1772780283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871625002522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":20,"alternative-id":["S0376871625002522"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112799","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mu-opioid mediated discriminative stimulus effects of fentanyl and xylazine: Dose-response and time-course studies","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112799","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112799"}}